Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18156013 | 1.00 | TSHR (0.50) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL8760081 | 1.00 | TSHR (0.50) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL10329372 | 0.82 | TSHR (0.48) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL12095052 | 0.81 | RORC (0.34) | TSHRRORCGABRA1GABRG2GABRB3 | |
| SCHEMBL701888 | 0.81 | RORC (0.34) | TSHRRORCGABRA1GABRG2GABRB3 | |
| SCHEMBL27734435 | 0.80 | TSHR (0.46) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL12095053 | 0.79 | TSHR (0.32) | TSHRRORCGABRA1GABRG2GABRB3 | |
| SCHEMBL701889 | 0.79 | TSHR (0.32) | TSHRRORCGABRA1GABRG2GABRB3 | |
| SCHEMBL18232629 | 0.78 | TSHR (0.44) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL16825297 | 0.77 | LMNA (0.40) | TSHRCHRM2CHRM4CHRM1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118435405-A | Lithium secondary battery | 西恩斯科公司 | 2024-08-02 | — | — | CN | claimed |
| CN-1455663-A | Novel aerosol formulation containing polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | CN | claimed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| US-20260106221-A1 | LITHIUM SECONDARY BATTERY WITH ENHANCED SAFETY | SOLVAY SPECIALTY POLYMERS IT (IT) | 2026-04-16 | — | — | US | disclosed |
| WO-2025131951-A1 | LITHIUM SECONDARY BATTERY WITH HIGH ENERGY DENSITY AND SAFETY | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2025-06-26 | — | — | WO | disclosed |
| CN-120019515-A | Lithium secondary battery with enhanced safety | 索尔维特殊聚合物意大利有限公司 | 2025-05-16 | — | — | CN | disclosed |
| WO-2025093455-A1 | LITHIUM SECONDARY BATTERY WITH ENHANCED ENERGY DENSITY | SPECIALTY OPERATIONS FRANCE (FR) | 2025-05-08 | — | — | WO | disclosed |
| EP-4454051-A1 | LITHIUM SECONDARY BATTERIES | SYENSQO SA (BE) | 2024-10-30 | — | — | EP | disclosed |
| CN-118435405-A | Lithium secondary battery | 西恩斯科公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240043593-A1 | Fluorine-Containing Polymer | CENTRAL GLASS COMPANY, LIMITED (JP) | 2024-02-08 | — | — | US | disclosed |
| US-5565593-A | FERROCENYL-1,1'-BIS(DIETHYPHOSPHONITE); CHEMICAL INTERMEDIATES FOR PREPERATION OF PHOSPHOLANE LIGANDS AND CHIRAL COMPLEXES, USEFUL AS CATALYSTS FOR CARRYING OUT ENANTIOSELECTIVE REACTIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| US-5559267-A | ENANTIOMORPHS, STEREOCHEMICAL CONTROL AND ASSYMETRIC INDUCTION, HYDROGENATION OF UNSATURATED ESTERS, COORDINATION CATALYSTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-09-24 | — | — | US | disclosed |
| US-5532395-A | HYDROGENATION CATALYSTS ) | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5386061-A | Reacting a bis(primary phosphine in the presence of a strong base with a cyclic sulfate; cyclization | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-01-31 | — | — | US | disclosed |
| US-5329015-A | Catalysts for stereospecific reactions | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-07-12 | — | — | US | disclosed |
| EP-0592552-A1 | CHIRAL PHOSPHOLANES VIA CHIRAL 1,4-DIOL CYCLIC SULFATES. | DU PONT (US) | 1994-04-20 | — | — | EP | disclosed |
| WO-1993001199-A1 | CHIRAL PHOSPHOLANES VIA CHIRAL 1,4-DIOL CYCLIC SULFATES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-01-21 | — | — | WO | disclosed |
| US-5171892-A | Chiral phospholanes via chiral 1,4-diol cyclic sulfates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260106221-A1 | LITHIUM SECONDARY BATTERY WITH ENHANCED SAFETY | BCL6B, CLCN2, SLC9A2 | TSHR 498/4885CHRM2 124/4885CHRM4 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.